HUP9902770A2 - Szövetregenerálódás modulátorai - Google Patents

Szövetregenerálódás modulátorai

Info

Publication number
HUP9902770A2
HUP9902770A2 HU9902770A HUP9902770A HUP9902770A2 HU P9902770 A2 HUP9902770 A2 HU P9902770A2 HU 9902770 A HU9902770 A HU 9902770A HU P9902770 A HUP9902770 A HU P9902770A HU P9902770 A2 HUP9902770 A2 HU P9902770A2
Authority
HU
Hungary
Prior art keywords
modulators
tissue regeneration
purified
new
nucleic acid
Prior art date
Application number
HU9902770A
Other languages
English (en)
Inventor
Joseph V. Bonventre
Richard L. Cate
Catherine A. Hession
Takaharu Ichimura
Michele Sanicola-Nadel
Henry Wei
Original Assignee
Biogen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26690881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9902770(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc. filed Critical Biogen Inc.
Publication of HUP9902770A2 publication Critical patent/HUP9902770A2/hu
Publication of HUP9902770A3 publication Critical patent/HUP9902770A3/hu
Publication of HU226205B1 publication Critical patent/HU226205B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)

Abstract

A találmány tárgyát vesesérüléssel kapcsőlatős mőlekűlák (rövidítve,,KIM") képezik, amelyek vesét ért sérülés űtán túlszabályzás alákerülnek a veseszövetben. A találmány tárgyát képezi tővábbá a fentifehérjéket kódőló, tisztítőtt és izőlált DNS-mőlekűla vagykőmplementer, vagy ezekkel hibridizálni képes DNS-mőlekűla, ennekrekőmbináns főrmája és a DNS-t tartalmazó vektőr. A találmány tárgya afenti KIM-fehérjékre specifikűs mőnőklőnális antitest és specifikűsantitestet termelő hibridóma sejtvőnal. A találmány tárgyét képezikdiagnősztikai módszerek, példáűl vesesérülés jelenlétének vagy afelszívódás főlyamatának meghatárőzására, vesebetegségben szenvedő,vagy vesebetegség kifejlődésének kőckázatát viselő alanyból származóvizeletben, szérűmban vagy vizeletüledékben lévő KIM-kőncentrációjánakmérésével. A találmány tárgyát képezik őlyan gyógyszerkészítmények is,amelyek KIM, KIM-variánsők, KIM-analógők, KIM fúziós fehérjék, KIM-agőnisták, KIM-re specifikűs antitestek vagy KIM-ligandűmők terápiásanhatásős mennyiségét tartalmazzák egy farmakőlógiailag elfőgadhatóhőrdőzóval együtt. ŕ
HU9902770A 1996-05-24 1997-05-23 Modulators of tissue regeneration HU226205B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1822896P 1996-05-24 1996-05-24
US2344296P 1996-08-23 1996-08-23
PCT/US1997/009303 WO1997044460A1 (en) 1996-05-24 1997-05-23 Modulators of tissue regeneration

Publications (3)

Publication Number Publication Date
HUP9902770A2 true HUP9902770A2 (hu) 1999-12-28
HUP9902770A3 HUP9902770A3 (en) 2001-09-28
HU226205B1 HU226205B1 (en) 2008-06-30

Family

ID=26690881

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902770A HU226205B1 (en) 1996-05-24 1997-05-23 Modulators of tissue regeneration

Country Status (27)

Country Link
US (4) US6664385B1 (hu)
EP (2) EP1655367A1 (hu)
JP (3) JP4602482B2 (hu)
CN (1) CN1147584C (hu)
AT (1) ATE318903T1 (hu)
AU (1) AU712289B2 (hu)
BG (1) BG64678B1 (hu)
BR (1) BR9709115A (hu)
CA (1) CA2257851C (hu)
CZ (1) CZ295936B6 (hu)
DE (1) DE69735364T3 (hu)
DK (1) DK0907735T5 (hu)
EA (1) EA004402B1 (hu)
EE (1) EE04817B1 (hu)
ES (1) ES2258793T5 (hu)
HK (1) HK1021746A1 (hu)
HU (1) HU226205B1 (hu)
IL (1) IL127162A (hu)
IS (1) IS2636B (hu)
NO (2) NO327597B1 (hu)
NZ (1) NZ336467A (hu)
PL (1) PL188826B1 (hu)
PT (1) PT907735E (hu)
SI (1) SI0907735T2 (hu)
SK (1) SK285461B6 (hu)
TR (1) TR199802421T2 (hu)
WO (1) WO1997044460A1 (hu)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1147584C (zh) * 1996-05-24 2004-04-28 拜奥根有限公司 组织再生调节物
EP0983357A1 (en) * 1997-05-23 2000-03-08 Biogen, Inc. Modulators of tissue regeneration
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CZ295108B6 (cs) 1998-03-20 2005-05-18 Benitec Australia Ltd Syntetický gen obsahující dispergovanou nebo cizorodou deoxyribonukleovou molekulu a genový konstrukt obsahující tento syntetický gen
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1160321A1 (en) * 2000-05-31 2001-12-05 Sanofi-Synthelabo Kidney Injury Novel Gene-1: Isolation and therapeutic applications
EP1305409B1 (en) 2000-06-16 2009-03-11 Biogen Idec MA Inc. Renal regulatory elements and methods of use thereof
US6812002B2 (en) * 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
JP4527394B2 (ja) * 2001-06-01 2010-08-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｋｉｍ−１の分断を阻害するための分子および方法
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
NZ530451A (en) 2001-06-29 2008-04-30 Univ Leland Stanford Junior TIM gene sequences and their use in immunological disorders and cancer
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
SI1585546T1 (sl) * 2002-12-30 2008-12-31 Biogen Idec Inc KIM-1 antagonisti in uporaba za moduliranje imunskega sistema
WO2004084823A2 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
ES2739463T3 (es) * 2003-03-27 2020-01-31 Childrens Hospital Med Ct Un método y kit para la detección de la instauración precoz de la lesión de células tubulares renales
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
JP2007536260A (ja) 2004-05-06 2007-12-13 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 虚血性および腎毒性障害の軽減および改善用ｎｇａｌ
RU2283666C9 (ru) * 2004-05-14 2007-03-10 Бизяев Алексей Вячеславович Средство для активации восстановления структуры и функции поврежденных тканей и органов
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
CN103751780A (zh) 2005-03-02 2014-04-30 比奥根艾迪克Ma公司 用于治疗th2介导的疾病的kim-1抗体
WO2007059082A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
EP2064553B2 (en) * 2006-08-07 2023-06-07 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090297479A1 (en) * 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
CN102187220B (zh) * 2008-08-28 2015-08-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
JP5947544B2 (ja) * 2008-08-29 2016-07-06 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
NZ619918A (en) * 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2740788C (en) * 2008-10-21 2023-03-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009313189B2 (en) 2008-11-10 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2528799T3 (es) * 2008-11-22 2015-02-12 Astute Medical, Inc. Métodos para el pronóstico de insuficiencia renal aguda
BRPI1007483B1 (pt) * 2009-01-28 2021-11-30 Bio Preventive Medicine Corporation Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2462440B1 (en) 2009-08-07 2017-05-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120264148A1 (en) * 2009-08-07 2012-10-18 Dashurie Nezieri Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013510322A (ja) 2009-11-07 2013-03-21 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN104698161A (zh) 2009-12-20 2015-06-10 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102791885B (zh) 2010-02-05 2015-09-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US9029093B2 (en) 2010-02-26 2015-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3339859A1 (en) 2010-06-23 2018-06-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DK2672980T3 (en) * 2011-02-09 2018-02-26 Lavivo Ab SYNBIOTIC COMPOSITIONS FOR GETTING UP AND RECONSTITUTING GAS MICROFLORA
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10420337B2 (en) * 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
WO2015134671A1 (en) 2014-03-04 2015-09-11 Targeson, Inc. Molecular imaging contrast agents and uses thereof
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0640094A1 (en) * 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1995021922A2 (en) * 1994-02-14 1995-08-17 Abbott Laboratories Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
US5622861A (en) * 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
EP0804547A4 (en) * 1994-08-18 1999-11-03 Univ Columbia ASSOCIATED SINGLE SEQUENCES OF KAPOSI DISEASE VIRUSES AND USE OF SAID SEQUENCES
US6069230A (en) * 1994-11-10 2000-05-30 Promega Corporation High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
CN1147584C (zh) * 1996-05-24 2004-04-28 拜奥根有限公司 组织再生调节物
EP1305409B1 (en) * 2000-06-16 2009-03-11 Biogen Idec MA Inc. Renal regulatory elements and methods of use thereof
JP4527394B2 (ja) * 2001-06-01 2010-08-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｋｉｍ−１の分断を阻害するための分子および方法
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
NZ530451A (en) * 2001-06-29 2008-04-30 Univ Leland Stanford Junior TIM gene sequences and their use in immunological disorders and cancer
US7215871B2 (en) * 2001-07-27 2007-05-08 Thomson Licensing Changing a playback speed for video presentation recorded in a field structure format
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
EP1467759A4 (en) * 2002-01-30 2006-05-31 Brigham & Womens Hospital COMPOSITIONS AND METHODS ASSOCIATED WITH TIM-3, TH1-SPECIFIC CELL SURFACE MOLECULE
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
SI1585546T1 (sl) * 2002-12-30 2008-12-31 Biogen Idec Inc KIM-1 antagonisti in uporaba za moduliranje imunskega sistema
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
AU2005231685A1 (en) * 2004-03-24 2005-10-20 Telos Pharmaceuticals Llc Compositions as adjuvants to improve immune responses to vaccines and methods of use

Also Published As

Publication number Publication date
JP2009039111A (ja) 2009-02-26
US20050089868A1 (en) 2005-04-28
ES2258793T3 (es) 2006-09-01
ES2258793T5 (es) 2010-01-25
HUP9902770A3 (en) 2001-09-28
JP2001505761A (ja) 2001-05-08
CN1223685A (zh) 1999-07-21
JP4316640B2 (ja) 2009-08-19
NO985427D0 (no) 1998-11-20
DK0907735T5 (da) 2010-06-14
BG64678B1 (bg) 2005-11-30
EE9800409A (et) 1999-06-15
AU3567697A (en) 1997-12-09
CZ295936B6 (cs) 2005-12-14
PL330313A1 (en) 1999-05-10
EP0907735B9 (en) 2010-05-19
ATE318903T1 (de) 2006-03-15
US20070141590A1 (en) 2007-06-21
IS2636B (is) 2010-06-15
EA004402B1 (ru) 2004-04-29
IL127162A (en) 2007-07-24
WO1997044460A1 (en) 1997-11-27
EP0907735B2 (en) 2009-10-07
AU712289B2 (en) 1999-11-04
CN1147584C (zh) 2004-04-28
SK160998A3 (en) 1999-07-12
EP0907735B1 (en) 2006-03-01
NO327597B1 (no) 2009-08-31
DE69735364D1 (de) 2006-04-27
PL188826B1 (pl) 2005-04-29
BR9709115A (pt) 1999-08-03
DE69735364T3 (de) 2010-05-06
EP1655367A1 (en) 2006-05-10
US20060286031A1 (en) 2006-12-21
SI0907735T1 (sl) 2006-08-31
TR199802421T2 (xx) 1999-02-22
SK285461B6 (sk) 2007-02-01
JP2008067701A (ja) 2008-03-27
HK1021746A1 (en) 2000-06-30
EE04817B1 (et) 2007-04-16
NO985427L (no) 1999-01-25
SI0907735T2 (sl) 2010-01-29
EA199801044A1 (ru) 1999-04-29
DK0907735T3 (da) 2006-06-26
IS4902A (is) 1998-11-20
NZ336467A (en) 2000-10-27
DE69735364T2 (de) 2006-11-30
NO20090945L (no) 1999-01-25
US6664385B1 (en) 2003-12-16
IL127162A0 (en) 1999-09-22
DK0907735T4 (da) 2009-12-21
CZ381398A3 (cs) 1999-05-12
JP4602482B2 (ja) 2010-12-22
PT907735E (pt) 2006-06-30
BG102967A (bg) 2000-05-31
HU226205B1 (en) 2008-06-30
CA2257851A1 (en) 1997-11-27
CA2257851C (en) 2011-11-15
EP0907735A1 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
HK1021746A1 (en) Modulators of tissue regeneration.
RU95110871A (ru) Способы определения нуклеотидной последовательности
CA2258502A1 (en) Modified factor viii
WO1997026270A3 (en) Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
DE69524365T2 (de) Verfahren zur Isolierung und Reinigung von 2'-Deoxy-2',2'-difluornucleosiden
AU9125198A (en) Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins
AU2277195A (en) Purified dna polymerase from bacillus stearothermophilus
AU3206095A (en) Neural cell adhesion molecules, nucleotide sequences encoding the molecules, and methods of use thereof
CA2262465A1 (en) Neuritin, a neurogene
WO1997023611A3 (de) Nukleinsäuresequenzen von genen der high mobility group proteine sowie verwendungen derselben
CA2200582A1 (en) Dna encoding human papillomavirus type 6a
EP0749312A4 (en) DIROFILARIA IMMITIS - Gp29 - PROTEINS, NUCLEIC ACID MOLECULES AND THEIR USE
FI962087A0 (fi) Olefiinien polymerointiin tarkoitettu stereospesifOlefiinien polymerointiin tarkoitettu stereospesifinen katalyyttisysteemi ja monivaiheiset polymeroiinen katalyyttisysteemi ja monivaiheiset polymerointiprosessit, joissa tätä systeemiä käytetään ntiprosessit, joissa tätä systeemiä käytetään
MX9806041A (es) Proteina purificada sr-p70.
AU4041997A (en) Dna purification procedure
AU3670395A (en) Hippocampus-associated proteins, dna sequences coding therefor and uses thereof
WO1994016085A3 (en) Hybrid proteins having cross-linking and tissue-binding activities
WO1998044134A3 (de) Bakterielle plasmide
DE69414375T2 (de) Verfahren zur herstellung von 1,1,1,2,2-pentafluoroethan, verfahren zur herstellung von 2,2-dichloro-1,1,1-trifluoroethan und verfahren zur reinigung von 1,1,1,2,2-pentafluoroethan
AU6550598A (en) Antithrombin protein and dna sequences
AU4595696A (en) Rna polymerase ii peptides and methods of use
DE69607582T2 (de) Verfahren zur Herstellung und Reinigung von 1,1,1-Tris(4-hydroxyphenyl)ethan
AU4804697A (en) Therapeutic compositions and methods for treating disease states with leukocyte adhesion inhibitor-1 (lai-1), and chemokine beta-11 (ckbeta-11)
AUPN986796A0 (en) Novel nucleic acid molecule and protein
MX9709596A (es) Adn catal ??tico.

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: THE GENERAL HOSPITAL CORPORATION, US

Free format text: FORMER OWNER(S): BIOGEN INC., US; BIOGEN INC., US

Owner name: BIOGEN IDEC MA, INC., US

Free format text: FORMER OWNER(S): BIOGEN INC., US; BIOGEN INC., US